Browsing by Author "Salas Sánchez, Cristian Osvaldo"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib
    (2025) Cabezas, David; Delgado Aguilar, Thalía; Sepúlveda Sánchez, Guisselle Alexandra; Krňávková, Petra; Vojáčková, Veronika; Kryštof, Vladimír; Strnad, Miroslav; Nicolás Ignacio, Silva Reyes; Echeverría, Javier; Espinosa Bustos, Christian Marcelo; Mellado, Guido; Luo, Jiao; Mella, Jaime; Salas Sánchez, Cristian Osvaldo
    Bcr-Abl inhibitors such as imatinib have been used to treat chronic myeloid leukemia (CML). However, the efficacy of these drugs has diminished due to mutations in the kinase domain, notably the T315I mutation. Therefore, in this study, new purine derivatives were designed as Bcr-Abl inhibitors based on 3D-QSAR studies. Methods: A database of 58 purines that inhibit Bcr-Abl was used to construct 3D-QSAR models. Using chemical information from these models, a small group of new purines was designed, synthesized, and evaluated in Bcr-Abl. Viability assays were conducted on imatinib-sensitive CML cells (K562 and KCL22) and imatinib-resistant cells (KCL22-B8). In silico analyses were performed to confirm the results. Results: Seven purines were easily synthesized (7a–g). Compounds 7a and 7c demonstrated the highest inhibition activity on Bcr-Abl (IC50 = 0.13 and 0.19 μM), surpassing the potency of imatinib (IC50 = 0.33 μM). 7c exhibited the highest potency, with GI50 = 0.30 μM on K562 cells and 1.54 μM on KCL22 cells. The GI50 values obtained for non-neoplastic HEK293T cells indicated that 7c was less toxic than imatinib. Interestingly, KCL22-B8 cells (expressing Bcr-AblT315I) showed greater sensitivity to 7e and 7f than to imatinib (GI50 = 13.80 and 15.43 vs. >20 μM, respectively). In silico analyses, including docking and molecular dynamics studies of Bcr-AblT315I, were conducted to elucidate the enhanced potency of 7e and 7f. Thus, this study provides in silico models to identify novel inhibitors that target a kinase of significance in CML.
  • No Thumbnail Available
    Item
    Synthesis, antitumoral activity, and in silico studies on Smoothened receptor of new 2,6,9-trisubstituted purine derivatives
    (Elsevier B.V., 2025) Espinosa Bustos, Christian Marcelo; Zarate Méndez, Ana María; Castro Álvarez, Alejandro; Guerrero, Simón; Kogan, Marcelo J.; Salas Sánchez, Cristian Osvaldo
    © 2024 Elsevier B.V.In this work, a series of 30 new 2,6,9-trisubstituted purine derivatives were synthesised and evaluated in silico as potential ligands of the Smoothened (SMO) receptor, as well as their ability to inhibit growth in Hedgehog (Hh)-dependent and Hh-independent cancer cell lines. The synthesis involved a convergent strategy, conventional methods and microwave irradiation. Initial antitumour evaluation was performed by testing cell growth inhibition in seven cancer cell lines and one non-neoplastic cell line (HEK-293) at 50 μM. IC50 values were determined for compounds showing < 50 % cell viability. Compounds 7l and 9j showed promising results with high cytotoxicity in three Hh-dependent cell lines and low cytotoxicity in HEK-293 cells. Compound 7l was more potent and selective than gemcitabine in BxPC-3, AsPc-1 and MIA-PaCa-2 cells and more than 5-fluorouracil in HT-29 cells, while 9j was more potent and selective than 5-fluorouracil in HCT116 and HT-29 cells. Molecular docking studies in SMO allowed the recognition of two binding sites related to ligand size and purine substitution patterns, while 7l bound to the top pocket (TMD-1), 9j bound to a deeper pocket (TMD-2). This study provides new evidence supporting the purine ring as a privileged scaffold for the development of new antitumour drugs targeting the SMO receptor.